Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sana Biotechnology Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.86 (market cap $8.04B), while Sana Biotechnology Inc trades at $3.53 (market cap $994.89M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 8.1× Sana Biotechnology Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| BIO | SANA | |
|---|---|---|
Market Cap | $8.04B | $994.89M |
Sector | Health | Health |
52-Week High | $339.75 | $5.92 |
52-Week Low | $241.71 | $2.68 |
Enterprise Value | $7.85B | $969.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
